Ken Griffin Hoth Therapeutics, Inc. Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.38 - $1.05 $4,130 - $11,413	-10,870 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$0.52 - $1.3 $5,652 - $14,131	10,870 New	10,870 $7,000
Q3 2021 Nov 15, 2021	SELL	$1.15 - $1.62 $53,355 - $75,161	-46,396 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$1.31 - $2.14 $43,704 - $71,394	-33,362 Reduced 41.83%	46,396 $74,000
Q1 2021 May 17, 2021	BUY	$1.85 - $3.04 $85,405 - $140,341	46,165 Added 137.42%	79,758 $157,000

Q4 2020 Feb 16, 2021	BUY	$1.58 - $2.37 $53,076 - $79,615	33,593 New	33,593 $80,000
Q2 2019 Aug 14, 2019	SELL	$4.76 - $8.1 $75,869 - $129,105	-15,939 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$5.15 - $8.53 $82,085 - $135,959	15,939 New	15,939 $0

Ticker HOTH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 1,288,470
Market Cap $1.17M
Description
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.